文章预览
First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 + bevacizumab (beva) in patients (pts) with advanced colorectal cancer (CRC): A phase I study Background IBI363 is a PD-1/IL-2α-bias bispecific antibody fusion protein which can block the PD-1 checkpoint and rejuvenate exhausted tumor-specific T cells by cis-activating the α-bias IL-2 receptor. IBI363 monotherapy showed acceptable safety and efficacy in pts with advanced non-microsatellite instability high/deficient mismatch repair (non-MSI-H/dMMR) CRC (Chen et al, abstract No. 3593 at 2024 ASCO annual meeting). We report initial safety and efficacy results of IBI363 + beva biosimilar in pts with advanced CRC in a phase I study. Methods Eligible pts with locally advanced or metastatic CRC (non-MSI-H/dMMR) who failed or intolerant of standard treatment were enrolled to receive IBI363 intravenously at 0.6-1.5 mg/kg + beva at 5/7.5 mg/kg. Primary objective was safety and tolerability; secondary objective was an
………………………………
